Merck

Merck agreed to acquire a vaccine manufacturing facility in Ireland from WuXi, the Irish Foreign Direct Investment Arm (IDA) announced today. IDA Ireland said the move comes as part of long-term plans in Ireland for Merck Sharp & Dohme (MSD), Rahway, New Jersey–based Merck’s Ireland business. The acquisition of the facility, located in Dundalk, brings…

Lotte Biologics and Merck recently signed a strategic partnership deal for biopharmaceutical manufacturing and process development. Through the agreement, Merck and Lotte Biologics will ensure the supply of essential raw materials and solutions for biopharmaceutical development and production, establish a stable supply chain system for raw materials, and develop a support system for the Bio…

Merck recently announced it initiated a Phase 3 clinical trial evaluating MK-1084 in combination with Keytruda for treating patients with metastatic non-small cell lung cancer (NSCLC). The Rahway, N.J.-based company is evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with Keytruda to treat patients with NSCLC whose tumors have KRAS G12C mutations…

Merck recently won FDA approval for its sotatercept-csrk Winrevair for treating adults with pulmonary arterial hypertension. The drug was approved to increase exercise capacity and reduce the risk of clinical worsening events, according to the Rahway, N.J.-based company. It previously received FDA breakthrough designation and is the first FDA-approved action signaling inhibitor therapy for pulmonary…

The pharmaceutical and biotech industries have experienced a surge of high-profile acquisitions and mergers in the first few months of the year, marking a notable trend in pharma M&A 2023. From Merck’s $11 billion acquisition of Prometheus Biosciences to Pfizer’s $43 billion purchase of Seagen, these deals highlight a focus on strengthening core assets and…

Senate Finance Committee Chair Ron Wyden (D-Oregon) wrote a letter demanding compliance from Merck and Abbott. The letter demands that Merck and Abbott comply with the Senate Finance Committee’s investigation into the tax practices of Big Pharma. According to a news release from the Senate Finance Committee, the two companies have, to this point, “stonewalled”…

Executives from Merck & Co. (NYSE:MRK) and Seagen (Nasdaq:SGEN) are reportedly considering a $40 billion acquisition deal. Readington, New Jersey–based Merck has offered to spend about $200 per share for Seagen, according to The Wall Street Journal. Executives from the company aim to finalize the deal before Merck announces its Q2 earnings on July 28, according…

Approximately one month after Seagen (Nasdaq:SGEN) CEO Clay Siegall resigned following a domestic abuse arrest, Merck & Co. (NYSE:MRK) is considering purchasing the company, according to WSJ. One potential hurdle is the possibility of increased antitrust enforcement from the DOJ and FTC focused on the pharmaceutical sector. To sidestep such risks, the two companies could enter a…

A number of patient advocates, including the Post-Finasteride Syndrome Foundation (PFSF), had petitioned the FDA to remove the anti-baldness drug Propecia (finasteride) from the market.  The FDA recently announced that the drug would remain on the market but agreed to revise the label for finasteride to include a notice about reports of suicidal behavior.  Merck…

Merck & Co. (NYSE:MRK) has revealed that Frank Clyburn, executive vice president and president, Human Health, will depart the company on Feb. 1, 2022. At Merck, Clyburn had P&L responsibility for almost 90% of Merck’s business. Clyburn will assume the CEO role at International Flavors & Fragrances (IFF/NYSE:IFF) on Feb. 14. “I’m excited to join…